Stay updated on Switching to Cabotegravir and Rilpivirine: Clinical Trial
Sign up to get notified when there's something new on the Switching to Cabotegravir and Rilpivirine: Clinical Trial page.

Latest updates to the Switching to Cabotegravir and Rilpivirine: Clinical Trial page
- CheckyesterdayChange DetectedSeveral existing study locations across the United States, Germany, Italy, South Africa, and Spain now have more specific postal codes or regional labels. The listed cities remain the same, with the update clarifying their location details.SummaryDifference1%

- Check8 days agoChange DetectedThe page now displays the clinical trial record, including study details, results measures, eligibility criteria, locations, and supporting documents, rather than a 403 error page.SummaryDifference100%

- Check15 days agoChange DetectedThe footer revision changes from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check22 days agoChange DetectedA site-wide banner announces that NIH is transitioning to the term “Super Intelligence” in place of “Artificial Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check29 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2 on the ClinicalTrials.gov error page.SummaryDifference0.2%

- Check36 days agoChange DetectedThe footer's site revision identifier updates from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

Stay in the know with updates to Switching to Cabotegravir and Rilpivirine: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Switching to Cabotegravir and Rilpivirine: Clinical Trial page.